Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This is a single center, phase I/Ib clinical trial evaluating the combination of the poly
adenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib with the DNA
methyltransferase (DNMT) inhibitor ASTX727, which is an oral formulation of decitabine with
cedazuridine (a cytidine deaminase inhibitor that allows for oral administration). The study
population consists of adults with advanced/metastatic solid tumor malignancies with germline
or somatic mutations in the HRR pathway (i.e., BReast CAncer gene 1 (BRCA1), BReast CAncer
gene 2(BRCA2), Partner And Localizer of BRCA2 (PALB2), ATM, and/or Checkpoint kinase 2
(CHEK2) mutations).
Phase:
Phase 1
Details
Lead Sponsor:
Pamela Munster
Collaborator:
National Cancer Institute (NCI)
Treatments:
Decitabine and cedazuridine drug combination Olaparib